Filanesib

Acute Myeloid Leukemia

PfizerSmall moleculePhase 1/2Dormant

CC

42/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 59/ 100

Competitive context

588 Active assets in the Acute Myeloid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Gemtuzumab M.D. Anderson Cancer Center	Phase 4	A
AMSACRINE University Hospital, Toulouse	Phase 4	BBB
Posaconazole AstraZeneca	Phase 4	BBB
(+)-VINCRISTINE Janssen Research & Development, LLC	Phase 3	BBB
Aclacinomycin Chinese PLA General Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Filanesib is also rated in:

plasma cell myelomaDormant

BBB

Indicative · Phase 2

76 / 100

plasma cell leukemiaDormant

CCC

Indicative · Phase 1/2

55 / 100

myelodysplastic syndromeDormant

CCC

Indicative · Phase 1/2

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.